Abstract: The present disclosure describes the C-type lectin CLEC11a as a bone growth factor. Clec11a-deficient mice showed reduced bone volume and mineralization, while bone resorption remained unchanged. Administration of recombinant Clec11a systemically promoted bone formation in mice at risk for osteoporosis.

Abstract: The present disclosure describes the C-type lectin CLEC11a as a bone growth factor. Clec11a-deficient mice showed reduced bone volume and mineralization, while bone resorption remained unchanged. Administration of recombinant Clec11a systemically promoted bone formation in mice at risk for osteoporosis.

Abstract: A matchmaking and geolocation mobile software application is designed for recruiting and professional networking. The software application allows users to have jobs and resumes attached to their public profiles, which are displayed on a map for others to see, pursue and engage. The software application can include three primary screens for user information, a map view, a user view and a list view. Users can see who is around them and the application can prioritize showing other users who have something in common. People will be able to know information about who is around them at a coffee shop, conference, or networking event prior to engaging with them in real time. Users will be able to broadcast jobs they represent to those around them and will be able to represent that job anywhere they go within the map view.

Abstract: The present disclosure describes the C-type lectin CLEC11a as a bone growth factor. Clec11a-deficient mice showed reduced bone volume and mineralization, while bone resorption remained unchanged. Administration of recombinant Clec11a systemically promoted bone formation in mice at risk for osteoporosis.

Abstract: A matchmaking and geolocation mobile software application is designed for recruiting and professional networking. The software application allows users to have jobs and resumes attached to their public profiles, which are displayed on a map for others to see, pursue and engage. The software application can include three primary screens for user information, a map view, a user view and a list view. Users can see who is around them and the application can prioritize showing other users who have something in common. People will be able to know information about who is around them at a coffee shop, conference, or networking event prior to engaging with them in real time. Users will be able to broadcast jobs they represent to those around them and will be able to represent that job anywhere they go within the map view.

Abstract: A matchmaking and geolocation mobile software application is designed for recruiting and professional networking. The software application allows users to have jobs and resumes attached to their public profiles, which are displayed on a map for others to see, pursue and engage. The software application can include three primary screens for user information, a map view, a user view and a list view. Users can see who is around them and the application can prioritize showing other users who have something in common. People will be able to know information about who is around them at a coffee shop, conference, or networking event prior to engaging with them in real time. Users will be able to broadcast jobs they represent to those around them and will be able to represent that job anywhere they go within the map view.

Abstract: The present disclosure relates to combination therapies for melanoma using anti-folates and/or inhibitors of ALDH1L1, ALDH1L2, or MTHFD1, and in particular, metastatic melanoma. Drugs for use in such combination include MEK inhibitors, BRAF inhibitors and cardiac glycosides.

Abstract: The present disclosure describes the C-type lectin CLEC11a as a bone growth factor. Clec11a-deficient mice showed reduced bone volume and mineralization, while bone resorption remained unchanged. Administration of recombinant Clec11a systemically promoted bone formation in mice at risk for osteoporosis.

Abstract: The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include MEK inhibitors combination with cardiac glycosides.

Abstract: The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include BRAF inhibitors such as PLX 4720 and PLX 4734 in combination with RO 31-8220, bafetinib or cardiac glycosides.

Abstract: The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include MEK inhibitors combination with cardiac glycosides.

Abstract: In one embodiment, a fulfillment request is received. A solution set comprising a plurality of fulfillment solutions is determined. The solution set, including values for fulfillment solutions according to a plurality of negotiation attributes, is presented. Selection of a negotiation attribute to be prioritized is invited. The solution set is redetermined according to a selected negotiation attribute. A redetermined solution set is presented. The fulfillment request is fulfilled according to a solution selected from the redetermined solution set.

Abstract: The present invention relates to mono- and combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include RO 31-8220, bafetinib, and cardiac glycosides.

Abstract: The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include BRAF inhibitors such as PLX 4720 and PLX 4734 in combination with RO 31-8220, bafetinib or cardiac glycosides.

Abstract: The present invention relates to methods of identifying, collecting and isolating hematopoietic stem cells (HSCs) and compositions of purified HSCs. Specifically, the present invention provides methods of isolating and purifying CD150+ HSCs, CD48? HSCs, and CD244? HSCs. The present invention also relates to purified cell samples with enriched CD150+ HSCs, CD48? HSCs, and CD244? HSCs populations, as well as methods of treating subjects with such compositions.

Abstract: In one embodiment, a fulfillment request is received. A solution set comprising a plurality of fulfillment solutions is determined. The solution set, including values for fulfillment solutions according to a plurality of negotiation attributes, is presented. Selection of a negotiation attribute to be prioritized is invited. The solution set is redetermined according to a selected negotiation attribute. A redetermined solution set is presented. The fulfillment request is fulfilled according to a solution selected from the redetermined solution set.

Abstract: The present invention relates to methods of identifying, collecting and isolating hematopoietic stem cells (HSCs) and compositions of purified HSCs. Specifically, the present invention provides methods of isolating and purifying CD150+ HSCs, CD48? HSCs, and CD244? HSCs. The present invention also relates to purified cell samples with enriched CD150+ HSCs, CD48? HSCs, and CD244? HSCs populations, as well as methods of treating subjects with such compositions.

Abstract: The present invention relates to methods of identifying, collecting and isolating hematopoietic stem cells (HSCs) and compositions of purified HSCs. Specifically, the present invention provides methods of isolating and purifying CD150+ HSCs, CD48? HSCs, and CD244? HSCs. The present invention also relates to purified cell samples with enriched CD150+ HSCs, CD48? HSCs, and CD244? HSCs populations, as well as methods of treating subjects with such compositions.

Abstract: The present invention relates to methods of identifying, collecting and isolating hematopoietic stem cells (HSCs) and compositions of purified HSCs. Specifically, the present invention provides methods of isolating and purifying CD150+ HSCs, CD48? HSCs, and CD244? HSCs. The present invention also relates to purified cell samples with enriched CD150+ HSCs, CD48? HSCs, and CD244? HSCs populations, as well as methods of treating subjects with such compositions.

Abstract: The present invention relates to methods of identifying, collecting and isolating hematopoietic stem cells (HSCs) and compositions of purified HSCs. Specifically, the present invention provides methods of isolating and purifying CD150+ HSCs, CD48? HSCs, and CD244? HSCs. The present invention also relates to purified cell samples with enriched CD150+ HSCs, CD48? HSCs, and CD244? HSCs populations, as well as methods of treating subjects with such compositions.